FLGR242

FLGR242 is a seller name for a claimed follistatin-albumin construct. The seller now publishes partial specifications, but the complete construct and independent characterization remain unresolved.

tier F · 0 independent characterizations located

verdict

The market description is now more specific, but it still does not establish a reproducible complete construct or the marketed 19-day pharmacokinetic claim.

what the seller says it is: The seller describes a follistatin-derived protein joined through a glycine-serine linker to an albumin-binding element, with a claimed mass near 40 kDa and affinity below 20 nM.

what remains unverified: The complete construct, independent analytical identity, folding, target and off-target binding, potency, sterility, and endotoxin burden remain unresolved in the located public record.

whether the half-life is 19 days: That is a seller presentation, not a compound-specific concentration-time result. No FLGR242 pharmacokinetic study was located.

No administration table is created because no FLGR242 animal or human administration study was located.

why F-tier

F-tier follows from the unresolved complete identity and empty administration record. More detailed seller copy does not substitute for independent characterization.

the core tension

The seller has moved beyond a bare name, but a detailed claim is still not an independently characterized test article.

what it is

The seller describes FLGR242 as a follistatin-derived protein fused through a glycine-serine linker to an albumin-binding element. It lists a molecular weight near 40 kDa, albumin affinity below 20 nM, and a lyophilized 10 mg presentation. These are seller claims. The complete construct and independent characterization are not established by the located paper, registry, or patent record.

what it does

Unknown for FLGR242. If the actual construct inhibited myostatin or related activin-family signaling, that would supply a conditional mechanism. No FLGR242-specific binding or functional assay located in this review establishes that step.

origin

The name is documented in research-chemical commerce. The accessible GLYCLOK patent describes a broad albumin-binding platform but does not identify FLGR242 or disclose an FLGR242 sequence or pharmacokinetic result.

why researchers are interested

The sales case joins a muscle-pathway claim to a long-exposure claim. Both depend on the marketed material being the stated construct, which has not been independently shown.

does it work

No FLGR242 animal or human administration study was located. The seller's 19-day presentation is not treated as measured pharmacokinetics, and evidence from other follistatin products is not transferred.

key facts

• molecular formula: not disclosed for the complete construct
• molecular weight: seller claim: about 40 kDa
• amino acids: complete sequence not independently established
• half-life: unknown; marketed 19-day claim lacks compound-specific PK
• type: seller-described follistatin fragment/linker/albumin-binding construct
• CAS: none verified
• 0 independent FLGR242 characterizations located
• 0 registered human studies located
• ~40 kDa seller-listed mass, not independent confirmation
• <20 nM seller-listed albumin affinity

frequently asked questions

What is FLGR242?

It is a seller name for a claimed follistatin-albumin construct. Partial seller specifications exist, while the complete construct and independent identity remain unresolved.

Does FLGR242 have a 19-day half-life?

No FLGR242-specific concentration-time study was located. The 19-day figure remains a seller claim.

Does the 40 kDa figure prove identity?

No. A seller-listed approximate mass does not establish the complete sequence, modification state, fold, binding, or potency.

Is there a studied route?

No. A lyophilized vial and bacteriostatic-water upsell are market presentations, not an administration study or validated route.

related peptides

• follistatin 344: different product identity and evidence record
• hgh: clinically characterized comparator; FLGR242 is not established as a GH agonist

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.